Objective: To examine the association between the extent of surgery and overall survival in a large contemporary cohort of patients with papillary thyroid cancer (PTC). Background: Guidelines recommend total thyroidectomy for PTC tumors > 1 cm, based on older data demonstrating an overall survival advantage for total thyroidectomy over lobectomy. Methods: Adult patients with PTC tumors 1.0-4.0 cm undergoing thyroidectomy in the National Cancer Database, 1998-2006, were included. Cox proportional hazards models were applied to measure the association between the extent of surgery and overall survival while adjusting for patient demographic and clinical factors, including comorbidities, extrathyroidal extension, multifocality, nodal and distant metastases, and radioactive iodine treatment. Results: Among 61,775 PTC patients, 54,926 underwent total thyroidectomy and 6849 lobectomy. Compared with lobectomy, patients undergoing total thyroidectomy had more nodal (7% vs 27%), extrathyroidal (5% vs16%), and multifocal disease (29% vs 44%) (all Ps < 0.001). Median follow-up was 82 months (range, 60-179 months). After multivariable adjustment, overall survival was similar in patients undergoing total thyroidectomy versus lobectomy for tumors 1.0-4.0 cm [hazard ratio (HR) = 0.96; 95% confidence interval (CI), 0.84-1.09); P = 0.54] and when stratified by tumor size: 1.0-2.0 cm [HR = 1.05; 95% CI, 0.88-1.26; P = 0.61] and 2.1-4.0 cm [HR = 0.89; 95% CI, 0.73-1.07; P = 0.21]. Older age, male sex, black race, lower income, tumor size, and presence of nodal or distant metastases were independently associated with compromised survival (P < 0.0001). Conclusions: Current guidelines suggest total thyroidectomy for PTC tumors >1 cm. However, we did not observe a survival advantage associated with total thyroidectomy compared with lobectomy. These findings call into question whether tumor size should be an absolute indication for total thyroidectomy.
T hyroid cancer is the most common malignancy of the endocrine system, with an estimated incidence of 60,220 in 2013 in the United States. 1 Papillary thyroid cancer (PTC) represents more than 90% of all thyroid cancer cases and is the most indolent form of the disease. 2 Prognosis is excellent, with 20-year survival surpassing 90% when appropriate therapy is undertaken. 3 The mainstay of treatment of PTC is surgical resection.
The current American Thyroid Association guidelines recommend total or near-total thyroidectomy for PTC tumors >1 cm. 4 This recommendation was supported by an analysis of populationlevel data from the National Cancer Database (NCDB) by Bilimoria et al 5 of 52,173 patients who underwent either total thyroidectomy or lobectomy for PTC tumors between 1985 and 1998. They found that total thyroidectomy was associated with better overall survival for PTC tumors ≥1 cm whereas extent of thyroid resection did not impact survival in patients with tumors <1 cm. 5 However, a subsequent analysis of data from 22,724 PTC patients (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) from the Surveillance, Epidemiology and End Results (SEER) database showed no survival difference between thyroid lobectomy and total thyroidectomy. 6 These conflicting findings have reopened the debate regarding the issue of the extent of surgery. Others have pointed out concerns with the Bilimoria et al multivariable analysis, as it did not account for potentially important factors such as comorbidities, multifocality, extrathyroidal extension, and completeness of resection. 7, 8 Therefore, we sought to examine the association between the extent of surgery and overall survival in relation to tumor size in a more contemporary NCDB cohort (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) while adjusting for patient demographic, clinical, and pathologic factors, including those that may have been confounders in prior studies.
The Duke University institutional review board granted this study an exemption status.
The NCDB participant user file was used to identify all patients with thyroid cancer who underwent thyroid surgery between 1998 and 2011. The following International Classification of Diseases for Oncology, Third Edition, codes were used to identify PTC patients: 8050/3, 8260/3, 8340/3, 8341/3, 8342/3, 8343/3. Aggressive histologic variants including columnar/tall cell, diffuse sclerosing, and insular variants were excluded from the study whenever identified. Patients younger than 18 years and those who did not undergo surgery were excluded. Patients with multiple cancer diagnoses were excluded to ensure that outcomes were not confounded by other cancer diagnoses and/or treatment. Only patients with tumor size 1.0-4.0 cm were included. The study was further restricted to cases diagnosed up to 2006 to only include cases with a minimum postoperative follow-up period of 5 years.
Patient variables including age at diagnosis, race, sex, level of education, annual income, insurance status, type of insurance, year of diagnosis, distance travelled to treating institution, and comorbidity were extracted from the database. Comorbidity was represented by the modified Charlson/Deyo scoring system (1992). 11 Annual income levels were assigned by the NCDB by linking a patient's zip code to the year 2000 US Census data. The NCDB reports median annual income data in the patient's zip code in quartiles. The lower 2 quartiles represent median income of less than $35,000 versus $35,000 or more for the top-2 quartiles.
The cohort was categorized into 2 groups based on the extent of surgery: patients who underwent lobectomy and patients who underwent total thyroidectomy. The lobectomy group included patients who underwent lobectomy with or without an isthmusectomy. The total thyroidectomy group included patients who underwent total, near-total, or subtotal thyroid resection. Patients who underwent completion thyroidectomy were coded as having had a total thyroidectomy. Patients were excluded if they had removal of less than a lobe or when the extent of surgery was not specified. Overall survival analyses were performed for all patients (tumors 1.0-4.0 cm) and for subgroups defined by tumor sizes 1.0-2.0 and 2.1-4.0 cm.
Statistical Analyses
Baseline characteristics were reported using frequencies and proportions for categorical variables. Descriptive data were compared across groups using the Kruskal-Wallis test for continuous variables and Pearson χ 2 or Fisher exact tests for categorical variables. Overall survival was defined from the time of diagnosis to the time of death or last follow-up. Survival time was censored for patients alive at the end of the study period. Patients with zero months of follow-up were excluded. Estimates and 95% confidence intervals (CIs) of overall survival proportions were computed using the Kaplan-Meier method, and survival distributions were compared across groups using the log-rank test.
A multivariable Cox proportional hazards model was used to examine the adjusted association of the extent of surgery and tumor size with overall survival. The model adjusted for the effects of patient, clinical, and tumor factors including age, sex, race, annual income, insurance status, hospital volume, patient comorbidities, tumor multifocality, extrathyroidal extension, lymph node involvement, distant metastases, surgical margin status, and radioactive iodine (RAI) treatment. The interaction of the extent of surgery and tumor size was not included in the final model, as it was not significant after adjustment. Graphical aids, including Schoenfeld residuals, score progress plots, and restricted cubic splines, were used to check the proportional hazards assumption of the variables included in the model.
In the NCDB, subtotal thyroidectomy shares the same code as near-total thyroidectomy. Near-total thyroidectomy is an accept-able alternative to total thyroidectomy for the treatment of thyroid cancer; therefore, patients who had subtotal thyroidectomy could not be excluded. To examine the effect of including patients who had subtotal thyroidectomy on the multivariable results, a subset analysis was performed excluding patients who had subtotal or near-total thyroidectomy.
Comorbidity data were not available in the NCDB before 2003, and extrathyroidal extension and multifocality were not available before 2004. These 3 variables are clinically important for covariate adjustment but have 50% to 60% missing values from 1998 to 2006. To address this issue in the main analysis, an additional level was introduced for each of the 3 aforementioned categorical variables to represent missing data (eg, data before 2004) and the variables were included in the model. Two sensitivity analyses were performed. The first sensitivity analysis modeled the effect of surgery on overall survival without adjusting for comorbidities, extrathyroidal extension, and multifocality. A second sensitivity analysis was limited to complete case analysis (ie, the 3 covariates were nonmissing).
RESULTS
There were 171,073 patients with thyroid cancer identified from the NCDB (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) ; 61,775 patients had PTC with tumors 1.0-4.0 cm and met the study criteria for inclusion. Of these, 6849 (11%) underwent thyroid lobectomy and 54,926 (89%) had total thyroidectomy (Table 1) . Of all study patients, 59% had tumors 1.0-2.0 cm and 41% had tumors 2.1-4.0 cm. Compared with patients undergoing lobectomy, those who had total thyroidectomy encompassed more tumors with multifocal disease (29% vs 44%), extrathyroidal extension (5% vs 16%), lymph node involvement (7% vs 27%), distant metastases (0.4% vs 1.0%), positive surgical margin status (7% vs 27%), and who received RAI treatment (33% vs 65%) (all Ps < 0.01).
The median follow-up time was 82 months (range, 60-179 months). Unadjusted overall survival was slightly better for patients who had total thyroidectomy than for those who had lobectomy at 5 years (97.2% vs 96.9%), 10 years (92.9% vs 91.4%), and 14 years (86.6% vs 84.4%) (P = 0.001) ( Fig. 1 ). Overall survival was inversely related to tumor size at 5 years (97.6% for tumors 1.0-2.0 cm, and 96.4% for tumors 2.1-4.0 cm), 10 years (94.0% for tumors 1.0-2.0 cm, and 91.0% for tumors 2.1-4.0 cm), and 14 years (88.0% vs 84.1%) (P < 0.001) ( Fig. 2 ).
After adjustment for patient demographic, clinical, and pathologic factors, overall survival was similar for total thyroidectomy compared with lobectomy in all patients (tumors 1.0-4.0 cm) [hazard ratio (HR) = 0.96; 95% CI, 0.84-1.09; P = 0.54]. When the analysis was stratified by tumor size, there were no significant differences in overall survival between total thyroidectomy and lobectomy for patients with tumors 1.0-2.0 cm (HR = 1.05; 95% CI, 0.88-1.26; P = 0.61) and 2.1-4.0 cm (HR = 0.89; 95% CI, 0.73-1.07; P = 0.21) ( Table 2) .
Patient factors independently associated with compromised overall survival included older patient age, male sex, black race, lower income, and higher comorbidity scores ( Table 2) . Tumor-and treatment-related factors independently associated with compromised overall survival included increasing tumor size, presence of lymph node and distant metastases, positive surgical margins, and lack of RAI treatment.
Sensitivity Analysis
To examine the effect of subtotal thyroidectomy on the association between the extent of surgery and overall survival, a subset analysis was performed excluding those who had subtotal/near-total thyroidectomy from the total thyroidectomy cohort; 5109 patients were excluded. The findings did not change; there were no differences A second sensitivity analysis was conducted to assess the impact of modeling the missing values for comorbidity, multifocality, and extrathyroidal extension on the association between the extent of surgery and overall survival. The multivariable models were repeated excluding these variables. Again, there were no differences in overall survival between patients undergoing total thyroidectomy and A third sensitivity analysis limited to patients with no missing variables (diagnosed in 2004 or later, when all variables were collected) was performed; similarly, we found no difference in overall survival among patients with tumors 1.0-4.0 cm (HR = 0.99; 95% CI, 0.76-1.29; P = 0.94) or when stratified by tumor size: 1.0-2.0 cm (HR = 1.18; 95% CI, 0.82-1.697; P = 0.36), and 2.1-4.0 cm (HR = 0.76; 95% CI, 0.52-1.12; P = 0.16).
DISCUSSION
In this study, we examined the association of the extent of surgery and tumor size on overall survival in a contemporary cohort of PTC patients from the NCDB (1998) (1999) (2000) (2001) (2002) (2003) (2004) (2005) (2006) . After adjusting for patient comorbidities, tumor multifocality, extrathyroidal extension, nodal disease, distant metastases, and completeness of resection, there was no survival advantage associated with undergoing total thyroidectomy over lobectomy for patients with tumors 1.0-4.0 cm. Upon further stratification, overall survival was similar between patients who underwent total thyroidectomy and those who underwent lobectomy for tumors 1.0-2.0 and 2.1-4.0 cm. Our findings call into question whether tumor size alone should be an absolute determinant for deciding optimal extent of thyroid surgery for PTC. Before the 2009 American Thyroid Association guidelines, the extent of surgery for differentiated thyroid cancer was a matter of considerable debate, as there was no evidence documenting a survival advantage with either lobectomy or total thyroidectomy. Proponents of total thyroidectomy argue that complete resection of thyroid tissue affords the opportunity to use RAI for postoperative detection and treatment of residual or metastatic disease and facilitates the use of serum thyroglobulin as a marker to detect residual disease and recurrence. 12, 13 Hypothetically, the use of total thyroidectomy could also eliminate the possibility of undetected multifocal disease in the contralateral lobe. 14 On the contrary, those who advocate for lobectomy point out that papillary thyroid carcinoma is an indolent disease with an excellent prognosis and that patients should not be subjected to higher risks for thyroidectomy-related complications such as hypoparathyroidism and recurrent laryngeal nerve injury without a clear survival benefit. 8 In our study, after multivariable adjustment for patient, clinical, and tumor factors, there was no survival advantage associated with total thyroidectomy versus lobectomy in PTC patients with tumors 1.0-4.0 cm at a median follow-up of 82 months (range, 60-179 months). Even when performing stratified analyses for patients with tumors 1.0-2.0 and 2.1-4.0 cm, no significant differences in overall survival were detected between patients undergoing total thyroidectomy and those undergoing lobectomy. Our findings are in disagreement with the previous study by Bilimoria et al in which they analyzed data from 52,173 patients from the NCDB who either had lobectomy or total thyroidectomy for PTC tumors between 1985 and 1998. After a median follow-up of 70 months, they found an overall survival difference associated with total thyroidectomy over lobectomy for tumors ≥1 cm. 5 In our study, in addition to having a longer median follow-up period, we were able to adjust for several important factors, such as patient comorbidities, which are known to have an impact on overall survival. In our study, comorbidity was a significant predictor of mortality. Tumor characteristics, such as extrathyroidal extension, multifocality, and completeness of surgical resection, were included in our multivariable models. These are well-known prognostic factors in thyroid cancer, and their presence correlates well with disease-specific mortality. 6, 7, 15, 16 The inclusion of these factors in our multivariable models strengthens our ability to make valid comparisons between surgery types. In addition, our analysis represents a more recent cohort from the NCDB (1998-2006 vs 1985-1998); completeness of data collection by participating registries and accuracy of administrative databases are expected to improve over time. The NCDB increased data quality assurance measures starting in 2002. 17 Our findings are consistent with a more recent report from the SEER database by Mendelsohn et al, 6 in which they analyzed data of 22,724 PTC patients (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) . They demonstrated that there was no survival difference between patients undergoing lobectomy and those undergoing total thyroidectomy. 6 Single-institution data also have failed to show a significant survival difference between patients undergoing total thyroidectomy and those undergoing lobectomy for PTC. 18, 19 Shah et al 19 analyzed data of 931 patients with differentiated thyroid cancer who underwent surgical treatment at a single institution. Patients undergoing lobectomy were matched to those who had total thyroidectomy, based on patient age, histology, tumor size, extrathyroidal extension, nodal disease, and distant metastases. This matched-pair analysis revealed no disease-specific survival difference between patients undergoing total thyroidectomy and those undergoing lobectomy at 20 years. 19 The limitations of our study include those inherent to studies from large databases such as the potential for coding errors. However, data reporting to the NCDB are highly standardized and heavily audited. 20 Given the fact that the database does not include information on disease recurrence or cause-specific mortality, these could not be included in our analysis. The strengths of our study lie in the large number of patients evaluated and the fact that it encompasses contemporary population-level data. Previous institutional studies have been limited by small numbers of patients, precluding adequate multivariable adjustment.
CONCLUSIONS
This study provides valuable information regarding the role of tumor size in determining the extent of thyroid surgery for papillary thyroid carcinoma. Although current guidelines suggest that tumor size alone should dictate the extent of surgery, we believe that tumor size is just one factor that should be considered in deciding the optimal extent of surgery. Total thyroidectomy may be indicated for many patients, including those who require RAI treatment in the adjuvant setting and those who have other high-risk features, such as extrathyroidal extension, nodal metastases, or distant metastases. However, total thyroidectomy is associated with higher risks of hypoparathyroidism and recurrent laryngeal nerve injury. This study may inform physicians and patients about overall survival benefits; the decision to perform lobectomy versus total thyroidectomy should be taken accounting for several important patient and disease factors to optimize quality of life.
DISCUSSANTS B. Cady (Providence, RI):
This study is an important contribution to the long-running controversy in differentiated thyroid cancer: what is the appropriate extent of primary organ removal to achieve the best balance between survival and the morbidity of therapy? It's always a pleasure to find support for one's biases, so I relish this opportunity to defend lobectomy.
This unusual cancer occurs largely (85%-90%) in younger, low-risk patients, the great majority of whom (75%-80%) are women. It's unusual also because the long-term outcome in low-risk patients is so excellent, 98% to 99% disease-free survival at 20 years, as documented by our Lahey clinic AMES risk criteria, the Mayo Clinic's more detailed MACIS scoring system, the TNM staging of the AJCC, and others. No molecular analysis has improved on these clinical prognostic indicators.
This surgical debate is particularly relevant today because, as you saw, the nearly 800% increase in clinical cases over the past 35 years in the United States by SEER registry data, from 8100 to 62,890 in 2014; however, the age-adjusted mortality rate has declined by 79%. Undoubtedly, this striking increase in cases is the result of increased diagnostic studies rather than inherent changes in disease behavior or incidence. I say this recognizing that the 13% autopsy incidence rate of PTC occurring in deaths from all causes in Americans.
Thus, in a population of more than 300 million, there are at least 39 million Americans harboring this cancer. Wider use, new types, and increased sophistication of diagnostic studies break into this huge pool of potential "cancers" to artifactually increase the number of clinical cases. The major problem, recognizing these data, is the near-universal overtreatment of these young patients, particularly the application of total thyroidectomy, which necessities lifelong medi- extremely poor adherence, allowing for unrecognized hypothyroidism in these patients later in life.
Total thyroidectomy is also accompanied by almost the routine use of RAI for remnant ablation, 65% in your study, despite no evidence that such RAI treatment improves outcome in low-risk patients. Thyroid-stimulating hormone suppression by iatrogenic therapeutic, not replacement, thyroid hormone administration, 6-monthly neck ultrasound search for lymph node metastases, which have no bearing on mortality in low-risk patients, and repeated thyroglobulin determinations checking for recurrence increase still further the treatment morbidity, all measures that cannot improve the near-perfect outcome. This long-term outcome in low-risk patients is not statistically different from an age-adjusted normal population.
In no other human cancer with a 99% 20-year survival rate is a policy of routine total primary organ removal practiced, nor routine adjuvant local and systemic therapy utilized. Therefore, this report may help tip the scales back toward a more measured balance between treatment and morbidity. Nowhere is the aphorism "Perfection is the enemy of good" more rationally applicable in the field of surgical oncology.
I have a couple of questions.
Having trained in environments committed to total thyroidectomy, how are the authors planning to change their practice over time? Second, what policies and tactics do you envision that would get the surgical and particularly the endocrinological communities to retreat from a misplaced and costly pursuit of an improved outcome that was already so good that it would be virtually impossible to improve?
Response From J.A. Sosa:
I think we all are the product of where we have been in our training. In the majority of cancers in my practice, I perform total thyroidectomy. Now, that may be because my practice is more biased toward high-risk patients who have nodal metastases and more locally advanced tumors. But I think we all have to recognize that we must be lifelong learners. As surgeons and surgeon scientists, we must work hard to collect evidence and then modify our practice in light of that evidence. Therefore, I approached this question perhaps as a skeptic.
But there is an increasing body of evidence supporting equivalence in overall survival between patients undergoing lobectomy and those undergoing total thyroidectomy. Certainly, it is the minority of studies that have demonstrated a survival benefit. Just a couple of weeks ago, Ito in Japan issued a very important study in World Journal of Surgery looking at 1088 patients. In his singleinstitution study in which he followed patients older than 18 years, he not only demonstrated equivalence in survival between patients undergoing lobectomy and those undergoing total thyroidectomy but also demonstrated comparability in recurrence-free survival, diseasespecific survival, and risk of recurrence.
In light of these data, I think it is probably time for guidelines to potentially reconsider this issue. I know later this spring or summer, the American Thyroid Association will be issuing guidelines. Certainly, we will all be reading with interest what it is going to recommend.
In terms of how to compel colleagues in endocrinology to read the same literature that we do, I think that is always a struggle. Just because guidelines exist does not mean that everyone knows about them or abides by them. Certainly, there is a body of data that suggest it is high-volume providers who are aware of the guidelines when in fact what we really want to assure is that these guidelines disseminate to all providers, including low-volume colleagues. I would challenge everyone in the room to continue to promote the science that underpins them.
DISCUSSANTS F. Nwariaku (Dallas, TX):
The one question I'll ask is, because most patients with earlystage thyroid cancer do well from a survival standpoint, and the main risk is recurrence, wouldn't recurrence be a better outcome to study? It seems like you excluded the patients who actually had more aggressive disease, large tumors, and histologic subtypes that were more aggressive, and those would be the ones at risk for early survival decreases.
Response From J.A. Sosa:
I think you are absolutely correct in saying that we need to be more sophisticated as a specialty in how we think about PTC and really all differentiated thyroid cancers. Through the work of others, we have now begun to think about PTC as low-risk, medium-risk, and highrisk tumors. In our analysis, we did not actually exclude most of these high-risk tumors. Rather, we adjusted for high-risk characteristics, including extrathyroidal extension and nodal and distant metastases.
When you adjust for these high-risk characteristics, the afforded overall survival benefit disappears. What I think we would argue is that there is equivalence in outcome for the majority of patients who have low-and medium-risk tumors. But for those patients who have high-risk tumors, as defined by some of these characteristics, then I think all of us could agree that total thyroidectomy, with or without RAI treatment, may be indicated. We would argue for a more sophisticated approach in terms of preoperative evaluation and risk stratification.
DISCUSSANTS

N. Estes (Peoria, IL):
I like your conclusion because I think we have done too much for these cancers. My question is, did you create in the lobectomyonly group the elimination of some high-risk cases by not picking up completion thyroidectomies, which can happen months later? That would have been identified in part when they were receiving or recommending RAI treatment sometime later.
Response From J.A. Sosa:
The nice thing about the NCDB is that it provides a longitudinal perspective on individual patients, as you can follow them through their course of care, whether it be surgery or adjuvant treatment postoperatively with either chemoradiation or, in our case, RAI treatment.
The patients who underwent lobectomy, followed by a completion thyroidectomy, were appropriately coded as patients undergoing total thyroidectomy.
DISCUSSANTS N. Estes (Peoria, IL):
And that was at the initial and the longitudinal? Because those data have to be given to each one of the hospitals.
Response From J.A. Sosa:
In the main body of our analysis, that is how they were treated.
DISCUSSANTS
C.R. McHenry (Cleveland, OH):
I wanted to raise the issue about how you stratified your patients. You stratified patients who had subtotal thyroidectomy into the total thyroidectomy group. I wondered if your results would have been different, one, if you had put the subtotal patients in the lobectomy group, or, ideally, it would have been best to categorize the patients as total thyroidectomy, subtotal thyroidectomy, and lobectomy?
Response From J.A. Sosa:
The decision to put subtotal thyroidectomy in the total thyroidectomy group is a convention that has been used by other authors. Our goal with this study was to be able to compare our results with those who have gone before us. For instance, in the Bilimoria et al study, that is how this relatively small subgroup was treated.
A separate question, I think, is whether everyone who says he or she does a near-total or total thyroidectomy actually does a neartotal or total thyroidectomy? Or, is a subtotal thyroidectomy a much more common phenomenon? There, I would refer to our colleagues at M.D. Anderson, who just published a study in JAMA Otolaryngology, where they looked at postoperative RAI uptake in a high-volume surgical series. What you see is that the uptakes in many patients were quite high, suggesting that near-total or total thyroidectomy is perhaps not as fastidious as many of us think that it is.
DISCUSSANTS
H. Chen (Madison, WI):
I just want to know whether your recommendation is based on your data. You have a 44-year-old woman, with 3.9-cm PTC tumor, with no worrisome features such as extrathyroidal extension metastases or lymph nodes. What would your recommendation be? The patient had no preference for lobectomy or total. What would you do?
Response From J.A. Sosa:
I think here the challenge is to avoid being led into a trap. The strength, I think, of our study is also its weakness. That is, the strength of this study is that it is looking at a population level and making observations about patients on average. I think the flip side of this, and a limitation of this kind of study, is that there is no such thing as the average patient. Each patient comes to us with a unique set of perspectives, preferences, life experiences, and findings on preoperative evaluation. I think it is impossible to take these results and fit them into a generic case. I think what the guidelines would argue, again, guidelines are evolving, is that more and more, we must do a more thorough preoperative evaluation of our patients, looking for high-risk characteristics; that is, using perhaps more cross-sectional imaging and more fastidious preoperative ultrasonography interrogating for extrathyroidal extension and nodal metastasis and for distant disease, because you want to exclude patients with high-risk features for which lobectomy may indeed not be equivalent to total thyroidectomy.
DISCUSSANTS
R.A. Prinz (Evanston, IL):
You have used the best tool we currently have, the NCDB, to look at this question. But just because it's the best doesn't mean it's the right or the correct tool.
You have already mentioned about the problems of not having disease-specific mortality or recurrence data, or the limited follow-up that's present in this database. But it seems to me that the 2 groups you are looking at are really not comparable because of the frequency of poor findings such as lymph node metastases, local invasion, and multifocality in the group that had total thyroidectomy. I think the real drawback is that you don't give us the reasoning of why each operation was done because that's just not available to you. I would just like to hear your comments on those issues.
Response From J.A. Sosa:
I think you are absolutely correct in saying that an unfortunate limitation of the population-level databases that I am aware of is that they do a poor job of measuring recurrence, which is obviously something of great interest.
To answer your question about recurrence, we would embark on a randomized prospective controlled trial. Dr Cady, in the past, has advocated for this, where we put head-to-head lobectomy versus total thyroidectomy. Although that has not been done in the United States, I would recommend the Ito article just published a couple of weeks ago. Again, it suggests in more than a thousand patients over 18 years of followup that recurrence rates, recurrence-free survival, disease-specific survival, and overall survival are equal between the two procedures.
Finally, I would say that we did our best in our study. Certainly, our median follow-up of 80 months is very long compared with the literature based on population-level data. But I still think there are clear limitations and shortcomings, and we cannot overstate the conclusions.
